drugset / Trial / NCT06824051

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

NCT06824051

Phase 1 Completed 120 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

Timeline

Start
2025-02-17
Primary completion
2026-01-26
Completion
2026-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Orforglipron Small molecule Oral

Indications